|
Volumn 12, Issue 11, 2001, Pages 722-729
|
Imiquimod 5% cream is a safe and effective self-applied treatment for anogenital warts - Results of an open-label, multicentre Phase IIIB trial
a a a a a a a |
Author keywords
Genital warts; Human papillomavirus; Imiquimod; Immune response modifiers; Treatment
|
Indexed keywords
IMIQUIMOD;
ADOLESCENT;
ADULT;
AGED;
ARTICLE;
CLINICAL TRIAL;
CONDYLOMA;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DISEASE SEVERITY;
DOSE RESPONSE;
DRUG EFFICACY;
DRUG SAFETY;
DRUG TOLERABILITY;
ERYTHEMA;
FEMALE;
FOLLOW UP;
HUMAN;
MAJOR CLINICAL STUDY;
MALE;
MULTICENTER STUDY;
PATIENT MONITORING;
PHASE 3 CLINICAL TRIAL;
PRIORITY JOURNAL;
RECURRENT DISEASE;
TREATMENT FAILURE;
WART VIRUS;
ADOLESCENT;
ADULT;
AGED;
AMINOQUINOLINES;
ANTI-INFECTIVE AGENTS;
CONDYLOMATA ACUMINATA;
CONSUMER PRODUCT SAFETY;
DEMOGRAPHY;
FEMALE;
FOLLOW-UP STUDIES;
HEALTH PERSONNEL;
HUMANS;
MALE;
MIDDLE AGED;
QUESTIONNAIRES;
RECURRENCE;
SELF ADMINISTRATION;
TREATMENT OUTCOME;
VAGINAL CREAMS, FOAMS, AND JELLIES;
|
EID: 0034756432
PISSN: 09564624
EISSN: None
Source Type: Journal
DOI: 10.1258/0956462011924218 Document Type: Article |
Times cited : (96)
|
References (18)
|